过表达富组氨酸糖蛋白质粒在体外抑制MHCC-97H肝癌细胞增殖

doi:10.3969/j.issn.1672-5069.2014.06.018

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (6): 632-636.doi: 10.3969/j.issn.1672-5069.2014.06.018

过表达富组氨酸糖蛋白质粒在体外抑制MHCC-97H肝癌细胞增殖

胡晓云

510515广州市南方医科大学南方医院感染病科肝脏肿瘤中心(胡晓云,廖毓菁,黄静,郭亚兵); 肿瘤内科（陈锦章）

收稿日期:2014-06-06 出版日期:2014-12-31 发布日期:2016-04-11
通讯作者: 郭亚兵,E-mail：gyabing@126.com
作者简介:胡晓云,女,26岁,硕士研究生。主要从事肝癌基础研究。E-mail：huxiaoyun143@163.com

Overexpression of histidine-rich glycoprotein plasmids inhibits cell proliferation of MHCC-97H cells in vitro

Hu Xiaoyun, Chen Jinzhang, Liao Yujing

Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong Province,China

Received:2014-06-06 Online:2014-12-31 Published:2016-04-11

摘要/Abstract

摘要： 目的检测原发性肝癌组织富组氨酸糖蛋白(HRG)的表达,及其在体外研究过表达富组氨酸糖蛋白质粒对肝癌细胞增殖能力的影响。方法采用免疫组化法检测8例肝癌组织HRG表达情况,采用Western blot法检测11例手术切除的肝癌组织和癌旁组织HRG表达的差异;在人肝癌细胞株MHCC-97H细胞中转染稳定过表达HRG质粒,使用流式细胞仪分析肝癌细胞的增殖能力。结果8例原发性肝癌组织HRG表达量较非肿瘤组织明显减少;另11例癌组织HRG表达量为（0.14±0.17）,癌旁组织HRG相对表达量为（1.39±2.08）,两者差异有统计学意义（P<0.05）;稳定过表达HRG的人肝癌细胞株MHCC-97H细胞增殖比例为（1.72±1.19）%,显著低于对照组 [（14.3±2.99）%,P<0.01]。结论原发性肝癌癌组织HRG表达明显减少,过表达HRG的肿瘤细胞增殖能力降低。

关键词: 原发性肝癌, 富组氨酸糖蛋白, 细胞增殖, 体外

Abstract: Objective To investigate the expression of histidine-rich glycoprotein（HRG） in hepatocellular carcinoma（HCC） and its impact on HCC cell proliferation. Methods Immunohistochemistry was used to detect the expression of HRG in 8 HCC specimens and Western blot to evaluate the expression of HRG in 11 surgical cancerous and its non-cancerous specimens. The cell proliferation was analyzed by flow cytometry after stable overexpression of HRG in MHCC-97H cells. Results Declined expression of HRG was found in all 8 cancerous tissues as compared to the non-tumor tissues;Similar results were obtained in 11 pairs of HCC and its para-carcinoma tissues;The relative expression of HRG/β-actin was（1.39±2.08） in para-carcinoma tissues, and （0.14 ± 0.17） in tumor tissue,with a significant difference between them（P<0.05）;The cell proliferation of MHCC-97H cells overexpressing HRG was remarkably inhibited as compared with the mock cells[（1.72±1.19）% vs.（14.3± 2.99）%,P<0.01]. Conclusion HRG is down-regulated in HCC and HRG overexpression can inhibit HCC cell proliferation in vitro.

Key words: Hepatocellular carcinoma, Histidine-rich glycoprotein, Cell proliferation, In vitro

胡晓云. 过表达富组氨酸糖蛋白质粒在体外抑制MHCC-97H肝癌细胞增殖[J]. 实用肝脏病杂志, 2014, 17(6): 632-636.

Hu Xiaoyun, Chen Jinzhang, Liao Yujing. Overexpression of histidine-rich glycoprotein plasmids inhibits cell proliferation of MHCC-97H cells in vitro[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 632-636.

参考文献

[1] Karrlander M,Lindberg N,Olofsson T,et al. Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. PLoS One,2009,4:e8536.
[2] Klenotic PA,Huang P,Palomo J,et al. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol,2010,176:2039-2050.
[3] Blank M,Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/autoimmune,vascular,and coagulation systems. Clin Rev Allergy Immunol,2008,34:307-312.
[4] Rolny C,Mazzone M,Tugues S,et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell, 2011,19:31-44.
[5] Olsson AK,Larsson H,Dixelius J,et al. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res,2004,64:599-605.
[6] Huang Y,Snuderl M,Jain RK. Polarization of tumor-associated macrophages:a novel strategy for vascular normalization and antitumor immunity. Cancer Cell,2011,19:1-2.
[7] Roberts AS,Campa MJ,Gottlin EB,et al. Identification of potential prognostic biomarkers in patients with untreated,advanced pancreatic cancer from a phase 3 trial（Cancer and Leukemia Group B 80303）. Cancer,2012,118:571-578.
[8] Tugues S,Honjo S,Konig C,et al. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res,2012,72: 1953-1963.
[9] Liu Y,He J,Li C,et al. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res,2010,9: 798-805.
[10] Poon IK,Patel KK,Davis DS,et al. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood,2011,117: 2093-2101.
[11] Thulin A,Ringvall M,Dimberg A,et al. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res,2009,7:1792-1802.
[12] Gorgani NN,Theofilopoulos AN. Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells:implications for ameliorating autoimmune diseases. Autoimmunity, 2007,40:260-266.
[13] 武彩萍,刘欣,李庆伟,等. 富组氨酸糖蛋白（HRG）的结构与功能. 中国生物和化学与分子生物学报,2012,28（1）：1-8.
[14] Poon IK,Hulett MD,Parish CR. Histidine-rich glycoprotein is a novel plasma pattern recognition molecule that recruits IgG to facilitate necrotic cell clearance via FcgammaRI on phagocytes. Blood,2010,115:2473-2482.
[15] Dixelius J,Olsson AK,Thulin A,et al. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res,2006,66:2089-2097.

过表达富组氨酸糖蛋白质粒在体外抑制MHCC-97H肝癌细胞增殖

Overexpression of histidine-rich glycoprotein plasmids inhibits cell proliferation of MHCC-97H cells in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[4]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[5]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[6]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[7]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[8]	郭丽平, 张成宏, 宁宝烁, 许敏, 徐贝贝, 王雪, 李异玲. 一种新生大鼠肝细胞分离改良方法的建立^*[J]. 实用肝脏病杂志, 2019, 22(1): 17-20.
[9]	张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.
[10]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[11]	陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.
[12]	姜哲, 舒敏, 王媛媛, 朴莲淑. miR-363靶向调控E2F3表达影响HepG2细胞增殖和凋亡研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 825-828.
[13]	徐溪, 党引利, 吴朔. HCV感染相关干扰素L4真核表达载体的构建与表达[J]. 实用肝脏病杂志, 2018, 21(6): 833-836.
[14]	闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.
[15]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.